| Year |
Title |
Altmetric |
| 2021
|
i-IFTA and chronic active T cell–mediated rejection: A tale of 2 (DeKAF) cohorts.
American Journal of Transplantation.
21:1866-1877.
2021
|
|
| 2021
|
Impact of Subclinical Borderline Inflammation on Kidney Transplant Outcomes.
Transplantation Direct.
2021
|
|
| 2021
|
Thirty Years of Tacrolimus in Clinical Practice.
Transplantation.
484-495.
2021
|
|
| 2020
|
Inflammation in areas of fibrosis: The DeKAF prospective cohort.
American Journal of Transplantation.
20:2509-2521.
2020
|
|
| 2020
|
Genome-wide association study for time to failure of kidney transplants from African American deceased donors.
Clinical Transplantation.
34.
2020
|
|
| 2020
|
Transplant physician and surgeon compensation: A sample framework accounting for nonbillable and value-based work.
American Journal of Transplantation.
20:641-652.
2020
|
|
| 2020
|
Late Graft Loss after Kidney Transplantation: Is "death with Function" Really Death with a Functioning Allograft?.
Transplantation.
1483-1490.
2020
|
|
| 2020
|
Redefining the Influence of Ethnicity on Simultaneous Kidney and Pancreas Transplantation Outcomes: A 15-year Single-center Experience.
Annals of Surgery.
271:177-183.
2020
|
|
| 2019
|
Tacrolimus troughs and genetic determinants of metabolism in kidney transplant recipients: A comparison of four ancestry groups.
American Journal of Transplantation.
19:2795-2804.
2019
|
|
| 2019
|
Identification of genetic variants associated with tacrolimus metabolism in kidney transplant recipients by extreme phenotype sampling and next generation sequencing
2019
|
|
| 2019
|
The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population.
American Journal of Transplantation.
19:2262-2273.
2019
|
|
| 2019
|
Variation in use of procurement biopsies and its implications for discard of deceased donor kidneys recovered for transplantation.
American Journal of Transplantation.
19:2241-2251.
2019
|
|
| 2019
|
Time for reform in transplant program–specific reporting: AST/ASTS transplant metrics taskforce.
American Journal of Transplantation.
19:1888-1895.
2019
|
|
| 2019
|
Long-term follow-up of the DeKAF cross-sectional cohort study.
American Journal of Transplantation.
19:1432-1443.
2019
|
|
| 2019
|
Chronic dialysis in patients with end-stage renal disease: Relevance to kidney xenotransplantation.
Xenotransplantation.
26.
2019
|
|
| 2019
|
Allograft and patient survival after sequential HSCT and kidney transplantation from the same donor—A multicenter analysis.
American Journal of Transplantation.
19:475-487.
2019
|
|
| 2018
|
Population Health, Ethnicity, and Rate of Living Donor Kidney Transplantation.
Transplantation.
102:2080-2087.
2018
|
|
| 2018
|
Apolipoprotein L1 and Chronic Kidney Disease Risk in Young Potential Living Kidney Donors.
Annals of Surgery.
267:1161-1168.
2018
|
|
| 2018
|
Expanding clarity or confusion? Volatility of the 5-tier ratings assessing quality of transplant centers in the United States.
American Journal of Transplantation.
18:1494-1501.
2018
|
|
| 2018
|
Late graft failure after kidney transplantation as the consequence of late versus early events.
American Journal of Transplantation.
18:1158-1167.
2018
|
|
| 2018
|
Xenotransplantation - The current status and prospects.
British Medical Bulletin.
125:5-14.
2018
|
|
| 2017
|
Effect of Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index.
American Journal of Transplantation.
17:1540-1548.
2017
|
|
| 2017
|
Obesity increases the risk of end-stage renal disease among living kidney donors.
Kidney International.
91:699-703.
2017
|
|
| 2017
|
Access to kidney transplantation among HIV-infected waitlist candidates.
Clinical Journal of the American Society of Nephrology.
12:467-475.
2017
|
|
| 2017
|
Cost-effectiveness of antibody-based induction therapy in deceased donor kidney transplantation in the United States.
Transplantation.
101:1234-1241.
2017
|
|
| 2016
|
APOL1 genotype and kidney transplantation outcomes from deceased african American donors.
Transplantation.
100:194-202.
2016
|
|
| 2016
|
IMPROVING LONG-TERM OUTCOMES IN KIDNEY TRANSPLANTATION: TOWARDS A NEW PARADIGM OF POST-TRANSPLANT CARE IN THE UNITED STATES
2016
|
|
| 2015
|
Moving beyond minimization trials in kidney transplantation.
Journal of the American Society of Nephrology.
26:2898-2901.
2015
|
|
| 2015
|
Medical management of chronic kidney disease in the renal transplant recipient.
Current Opinion in Nephrology and Hypertension.
24:587-593.
2015
|
|
| 2015
|
Deceased donor multidrug resistance protein 1 and caveolin 1 gene variants may influence allograft survival in kidney transplantation.
Kidney International.
88:584-592.
2015
|
|
| 2015
|
Apolipoprotein L1 gene variants in deceased organ donors are associated with renal allograft failure.
American Journal of Transplantation.
15:1615-1622.
2015
|
|
| 2015
|
Reassessing medical risk in living kidney donors.
Journal of the American Society of Nephrology.
26:1017-1019.
2015
|
|
| 2015
|
Identification of strategies to facilitate organ donation among african americans using the nominal group technique.
Clinical Journal of the American Society of Nephrology.
10:286-293.
2015
|
|
| 2015
|
Through a glass darkly: Seeking clarity in preventing late kidney transplant failure.
Journal of the American Society of Nephrology.
26:20-29.
2015
|
|
| 2014
|
Kidneys at higher risk of discard: Expanding the role of dual kidney transplantation.
American Journal of Transplantation.
14:404-415.
2014
|
|
| 2014
|
Kidney donors at increased risk? Additional studies are needed.
Kidney International.
86:650.
2014
|
|
| 2014
|
The high cost of organ transplant commercialism.
Kidney International.
86:858-859.
2014
|
|
| 2013
|
Future of medicare immunosuppressive drug coverage for kidney transplant recipients in the United States.
Clinical Journal of the American Society of Nephrology.
8:1258-1266.
2013
|
|
| 2012
|
Erratum: A realistic proposal-incentives may increase donation - We need trials now! (American Journal of Transplantation (2012) 12 (1957-1958) DOI:10.1111/j.1600-6143.2012.04117.x).
American Journal of Transplantation.
12:2261.
2012
|
|
| 2012
|
Report of a consensus conference on transplant program quality and surveillance.
American Journal of Transplantation.
12:1988-1996.
2012
|
|
| 2012
|
The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival.
American Journal of Transplantation.
12:1924-1928.
2012
|
|
| 2012
|
Review of cytomegalovirus infection findings with mammalian target of rapamycin inhibitor-based immunosuppressive therapy in de novo renal transplant recipients.
Transplantation.
93:1075-1085.
2012
|
|
| 2012
|
Counseling patients for kidney transplantation: Awkward conversations?.
American Journal of Transplantation.
12:273-274.
2012
|
|
| 2012
|
A realistic proposal - Incentives may increase donation - We need trials now!.
American Journal of Transplantation.
12:1957-1958.
2012
|
|
| 2011
|
Our evolving understanding of late kidney allograft failure.
Current Opinion in Organ Transplantation.
16:594-599.
2011
|
|
| 2011
|
The PROMISE study: A phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de Novo kidney transplantation.
American Journal of Transplantation.
11:2675-2684.
2011
|
|
| 2011
|
Therapeutic drug monitoring of mycophenolates in kidney transplantation: Report of The Transplantation Society consensus meeting.
Transplantation Reviews.
25:58-64.
2011
|
|
| 2011
|
Advances in kidney transplant immunosuppression: Emerging biologics.
Dialysis and Transplantation.
40:30-32.
2011
|
|
| 2011
|
Prevention of cardiovascular disease in adult recipients of kidney transplants
2011
|
|
| 2010
|
Living donor nephrectomy: Understanding long-term risk in minority populations.
American Journal of Transplantation.
10:2574-2576.
2010
|
|
| 2010
|
Optimal cutoff point for immunoperoxidase detection of C4d in the renal allograft: Results from a multicenter study.
Transplantation.
90:1099-1105.
2010
|
|
| 2010
|
Inflammation in areas of tubular atrophy in kidney allograft biopsies: A potent predictor of allograft failure.
American Journal of Transplantation.
10:2066-2073.
2010
|
|
| 2010
|
Evidence for antibody-mediated injury as a Major determinant of late kidney allograft failure.
Transplantation.
90:68-74.
2010
|
|
| 2010
|
Optimizing medication adherence: An ongoing opportunity to improve outcomes after kidney transplantation.
Clinical Journal of the American Society of Nephrology.
5:1305-1311.
2010
|
|
| 2010
|
Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: Preliminary data from the DeKAF study.
American Journal of Transplantation.
10:315-323.
2010
|
|
| 2010
|
Pathological and clinical characterization of the 'Troubled transplant': Data from the DeKAF study.
American Journal of Transplantation.
10:324-330.
2010
|
|
| 2010
|
Mycophenolic acid exposure in high-and low-weight renal transplant patients after dosing with mycophenolate mofetil in the opticept trial.
Therapeutic Drug Monitoring.
32:224-227.
2010
|
|
| 2009
|
Chronic calcineurin inhibitor nephrotoxicity: Reflections on an evolving paradigm.
Clinical Journal of the American Society of Nephrology.
4:2029-2034.
2009
|
|
| 2009
|
Barriers to preemptive kidney transplantation.
American Journal of Nursing.
109:28-37.
2009
|
|
| 2009
|
Use of cardioprotective medications in kidney transplant recipients.
American Journal of Transplantation.
9:1811-1815.
2009
|
|
| 2009
|
Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: The opticept trial.
American Journal of Transplantation.
9:1607-1619.
2009
|
|
| 2009
|
Transplant tourism and unregulated black-market trafficking of organs.
American Journal of Transplantation.
9:1484.
2009
|
|
| 2009
|
A Festschrift honoring Dr. John J. Curtis..
Clinical Journal of the American Society of Nephrology.
4:2027-2028.
2009
|
|
| 2009
|
Bortezomib successfully reduces monoclonal serum free light chain levels in a patient with recurrent myeloma and cast nephropathy in the renal transplant..
Clinical Transplants.
439-441.
2009
|
|
| 2009
|
Must health literacy be a prerequisite for kidney transplantation?.
Clinical Journal of the American Society of Nephrology.
4:16-17.
2009
|
|
| 2008
|
Phase 1 dose-escalation study of CP-690 550 in stable renal allograft recipients: Preliminary findings of safety, tolerability, effects on lymphocyte subsets and pharmacokinetics.
American Journal of Transplantation.
8:1711-1718.
2008
|
|
| 2008
|
Transplant tourism: A modern iteration of an ancient problem.
Current Opinion in Organ Transplantation.
13:395-399.
2008
|
|
| 2008
|
Systolic dysfunction portends increased mortality among those waiting for renal transplant.
Journal of the American Society of Nephrology.
19:1190-1196.
2008
|
|
| 2008
|
Kidney transplantation as primary therapy for end-stage renal disease: A National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQI™) conference.
Clinical Journal of the American Society of Nephrology.
3:471-480.
2008
|
|
| 2007
|
The impact of left ventricular systolic dysfunction on survival after renal transplantation.
Transplantation.
84:1610-1617.
2007
|
|
| 2007
|
Role of β3 integrin in acute renal allograft rejection in humans.
Clinical Journal of the American Society of Nephrology.
2:1268-1273.
2007
|
|
| 2007
|
Must all living donor compensation be viewed as valuable consideration? [2].
American Journal of Transplantation.
7:1309-1310.
2007
|
|
| 2007
|
Racial Disparities in Renal Allograft Survival: A Public Health Issue?.
Journal of The American College of Surgeons.
204:894-902.
2007
|
|
| 2006
|
Limiting financial disincentives in live organ donation: A rational solution to the kidney shortage.
American Journal of Transplantation.
6:2548-2555.
2006
|
|
| 2006
|
The conspicuous costs of more of the same.
American Journal of Transplantation.
6:1503-1504.
2006
|
|
| 2006
|
Current and evolving immunosuppressive regimens in kidney transplantation.
American Journal of Kidney Diseases.
47.
2006
|
|
| 2005
|
The relationship between ethnicity and outcomes in solid organ transplantation.
Journal of Pediatrics.
147:721-723.
2005
|
|
| 2005
|
Understanding the influence of ethnicity on renal allograft survival.
American Journal of Transplantation.
5:2603-2604.
2005
|
|
| 2005
|
Mycophenolate mofetil: Ten years of clinical experience. Introduction.
Transplantation.
80.
2005
|
|
| 2005
|
Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts.
American Journal of Transplantation.
5:2248-2252.
2005
|
|
| 2005
|
Kidneys from deceased donors: Maximizing the value of a scarce resource.
American Journal of Transplantation.
5:1725-1730.
2005
|
|
| 2005
|
Long-term deterioration of kidney allograft function.
American Journal of Transplantation.
5:1405-1414.
2005
|
|
| 2005
|
Improving access to renal transplantation.
Seminars in Dialysis.
18:482-486.
2005
|
|
| 2004
|
"High-risk" renal transplantation: evolving definitions at a single center..
Clinical Transplants.
121-126.
2004
|
|
| 2004
|
Transplantation in the diabetic patient with advanced chronic kidney disease: A task force report.
American Journal of Kidney Diseases.
44:529-542.
2004
|
|
| 2004
|
Whither Living Donors?.
American Journal of Transplantation.
4:2-3.
2004
|
|
| 2003
|
Equivalent Pharmacokinetics of Mycophenolate Mofetil in African-American and Caucasian Male and Female Stable Renal Allograft Recipients.
American Journal of Transplantation.
3:1581-1586.
2003
|
|
| 2003
|
Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporin and steroids in renal transplantation.
Clinical Transplantation.
17:511-517.
2003
|
|
| 2003
|
Determinants of cardiovascular mortality after renal transplantation: A role for cytomegalovirus?.
American Journal of Transplantation.
3:79-81.
2003
|
|
| 2003
|
Diabetes mellitus after kidney transplantation.
American Journal of Transplantation.
3:512-513.
2003
|
|
| 2003
|
The report of a national conference on the wait list for kidney transplantation.
American Journal of Transplantation.
3:775-785.
2003
|
|
| 2002
|
The nondirected live-kidney donor: Ethical considerations and practice guidelines. A national conference report.
Transplantation.
74:582-589.
2002
|
|
| 2002
|
Addressing minority issues in renal transplantation: Is more equitable access an achievable goal?.
American Journal of Transplantation.
2:1-3.
2002
|
|
| 2002
|
African Americans and renal transplantation: Disproportionate need, limited access, and impaired outcomes.
American Journal of the Medical Sciences.
323:94-99.
2002
|
|
| 2001
|
Noncomplication in solid organ transplantation.
Current Opinion in Organ Transplantation.
6:164-168.
2001
|
|
| 2001
|
Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow-up.
Transplantation.
71:1681-1683.
2001
|
|
| 2001
|
Evolution of immunosuppression and continued importance of acute rejection in renal transplantation.
American Journal of Kidney Diseases.
38.
2001
|
|
| 2001
|
Maintenance immunosuppression in the renal transplant recipient: An overview.
American Journal of Kidney Diseases.
38.
2001
|
|
| 2000
|
Renal transplantation in black Americans.
New England Journal of Medicine.
343:1545-1552.
2000
|
|
| 2000
|
Recommendations for the outpatient surveillance of renal transplant recipients.
Journal of the American Society of Nephrology.
11.
2000
|
|
| 2000
|
Prediction of renal transplant survival from early postoperative radioisotope studies.
Journal of Nuclear Medicine.
41:1332-1336.
2000
|
|
| 2000
|
Posttransplant lymphoproliferative disorder localized near the allograft in renal transplantation.
Transplantation.
69:809-814.
2000
|
|
| 2000
|
Erratum: Potential utility of rapamycin and tacrolimus in long-term, low-toxicity regimens (Transplantation Proceedings Vol. 31 (Suppl. 8A) (1999) (17S-22S)).
Transplantation Proceedings.
32:503-504.
2000
|
|
| 1999
|
Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection.
Transplantation.
68:310-313.
1999
|
|
| 1999
|
Potential utility of rapamycin and tacrolimus in long-term, low-toxicity regimens.
Transplantation Proceedings.
31:17-22.
1999
|
|
| 1998
|
Development and clinical utility of daclizumab (Zenapax®), a humanized anti-Tac monoclonal antibody, in renal transplantation.
Todays Therapeutic Trends.
16:309-324.
1998
|
|
| 1998
|
Stumbling toward equity: The role of government in kidney transplantation.
University of Illinois Law Review.
703.
1998
|
|
| 1998
|
Stumbling toward equity: the role of government in kidney transplantation..
University of Illinois Law Review.
1998:703-725.
1998
|
|
| 1998
|
Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation.
Transplantation.
66:29-37.
1998
|
|
| 1998
|
Losartan, an Angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis.
Journal of the American Society of Nephrology.
9:1104-1108.
1998
|
|
| 1998
|
Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation.
New England Journal of Medicine.
338:161-165.
1998
|
|
| 1996
|
The evaluation of living renal transplant donors: Clinical practice guidelines.
Journal of the American Society of Nephrology.
7:2288-2313.
1996
|
|
| 1996
|
Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3 - A randomized, double-blind placebo-controlled study.
Transplantation.
61:573-577.
1996
|
|
| 1996
|
Impact of donor/recipient size matching on outcomes in renal transplantation.
Transplantation.
61:383-388.
1996
|
|
| 1996
|
Benefits of continued cyclosporine through an indigent drug program.
American Journal of Kidney Diseases.
28:572-577.
1996
|
|
| 1996
|
Dilemmas in renal transplantation: When the clinical course and histological findings differ.
American Journal of Kidney Diseases.
27:435-440.
1996
|
|
| 1996
|
Factors affecting renal allograft survival in african americans?.
Blood Purification.
14:327-333.
1996
|
|
| 1995
|
Evaluation of living renal donors: The current practice of US transplant centers.
Transplantation.
60:322-327.
1995
|
|
| 1995
|
HLA matching in renal transplantation.
New England Journal of Medicine.
332:752-753.
1995
|
|
| 1995
|
Cyclosporine inhibits the renal response to L-arginine in human kidney transplant recipients.
Journal of the American Society of Nephrology.
5:1426-1433.
1995
|
|
| 1995
|
Progress in Renal Transplantation a Single Center Study of 3359 Patients over 25 Years.
Annals of Surgery.
221:446-458.
1995
|
|
| 1995
|
The evaluation of renal transplant candidates: Clinical practice guidelines.
Journal of the American Society of Nephrology.
6:1-34.
1995
|
|
| 1994
|
Delayed graft function after renal transplantation: Causes, implications, and clinical management.
Journal of Nephrology.
7:313-321.
1994
|
|
| 1994
|
In Reply
1994
|
|
| 1994
|
Race and Allocation of Kidneys for Transplantation
1994
|
|
| 1994
|
Cytokines and transplantation: a clinical perspective..
Transplantation science.
4 Suppl 1.
1994
|
|
| 1994
|
Erythropoiesis after withdrawal of enalapril in post-transplant erythrocytosis.
Kidney International.
46:1397-1403.
1994
|
|
| 1994
|
Posttransplant Erythrocytosis: An Enigma Revisited.
American Journal of Kidney Diseases.
24:1-11.
1994
|
|
| 1994
|
Renal retransplantation: The role of race, quadruple immunosuppression, and the flow cytometry cross-match.
Transplantation.
57:47-54.
1994
|
|
| 1993
|
Racial Equity in Renal Transplantation: The Disparate Impact of HLA-Based Allocation
1993
|
|
| 1993
|
Unequal racial access to kidney transplantation..
Vanderbilt Law Review.
46:805-863.
1993
|
|
| 1993
|
Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients.
Journal of the American Society of Nephrology.
3:1570-1574.
1993
|
|
| 1993
|
Experience with mycophenolate mofetil (RS61443) in renal transplantation at a single center.
Annals of Surgery.
217:476-484.
1993
|
|
| 1993
|
Tapering or Discontinuing Cyclosporine for Financial Reasons—A Single-Center Experience.
American Journal of Kidney Diseases.
21:9-15.
1993
|
|
| 1992
|
Benefits of quadruple immunosuppressive therapy in recipients of living related donor kidneys: A review of 855 operations.
Annals of Surgery.
215:606-617.
1992
|
|
| 1992
|
Improved survival of primary cadaveric renal allografts in blacks with quadruple immunosuppression.
Transplantation.
53:103-109.
1992
|
|
| 1992
|
The impact of the UNOS mandatory sharing policy on recipients of the black and white races-experience at a single renal transplant center.
Transplantation.
53:770-774.
1992
|
|
| 1991
|
Immunosuppression tailored to race.
Clinical Transplantation.
5:580-582.
1991
|
|
| 1991
|
Analysis of 22 years experience in living-related transplantation at the University of Alabama in Birmingham..
Clinical Transplants.
179-191.
1991
|
|
| 1991
|
Effects of enalapril on erythrocytosis after renal transplantation.
Annals of Internal Medicine.
115:954-955.
1991
|
|
| 1991
|
OKT3 first-dose reaction: Association with T cell subsets and cytokine release.
Kidney International.
39:141-148.
1991
|
|
| 1990
|
Donor antigen-specific immunosuppression in cadaveric and living-related donor kidney allograft recipients..
Clinical Transplants.
289-300.
1990
|
|
